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Abstract
Objectives Positron emission tomography-computed tomog-
raphy (PET/CT) with fluorine-18-fluorodeoxy-D-glucose
(FDG) has evolved from a research modality to an invaluable
tool in head and neck cancer imaging. However, interpretation
of FDG PET/CT studies may be difficult due to the inherently
complex anatomical landmarks, certain physiological variants
and unusual patterns of high FDG uptake in the head and
neck. The purpose of this article is to provide a comprehensive
approach to key imaging features and interpretation pitfalls of
FDG-PET/CT of the head and neck and how to avoid them.
Methods We review the pathophysiological mechanisms lead-
ing to potentially false-positive and false-negative assessments,
and we discuss the complementary use of high-resolution
contrast-enhanced head and neck PET/CT (HR HN PET/CT)
and additional cross-sectional imaging techniques, including
ultrasound (US) and magnetic resonance imaging (MRI).
Results The commonly encountered false-positive PET/CT in-
terpretation pitfalls are due to high FDG uptake by physiological
causes, benign thyroid nodules, unilateral cranial nerve palsy and
increased FDG uptake due to inflammation, recent chemoradio-
therapy and surgery. False-negative findings are caused by lesion
vicinity to structures with high glucose metabolism, obscuration
of FDG uptake by dental hardware, inadequate PET scanner
resolution and inherent low FDG-avidity of some tumours.
Conclusions The interpreting physician must be aware of these
unusual patterns of FDG uptake, as well as limitations of PET/CT
as a modality, in order to avoid overdiagnosis of benign condi-
tions as malignancy, as well as missing out on actual pathology.
Teaching points
• Knowledge of key imaging features of physiological and
non-physiological FDG uptake is essential for the interpre-
tation of head and neck PET/CT studies.
• Precise anatomical evaluation and correlation with
contrast-enhanced CT, US or MRI avoid PET/CT
misinterpretation.
• Awareness of unusual FDG uptake patterns avoids overdi-
agnosis of benign conditions as malignancy.
Keywords Positron emission tomography-computed tomog-
raphy (PET/CT) . Pitfalls . Head and neck tumours
Introduction
Positron emission tomography-computed tomography (PET/
CT) with fluorine-18-fluorodeoxy-D-glucose (FDG) plays a ma-
jor role today in the pre-therapeutic work-up and post-therapeutic
monitoring of patients with head and neck tumours. FDG-PET/
CT is now routinely used in the head and neck for the delineation
of the primary tumour, detection of regional nodal metastases,
distant metastases and second primary tumours. Further indica-
tions include assessment of post-treatment response, long-term
surveillance to detect recurrence and, last but not least, detection
of an unknown primary tumour [1–5]. Thus, FDG-PET/CT
tremendously facilitates the management of head and neck can-
cer patients in whom treatment is often expensive and associated
with a significant morbidity [1–4]. However, the interpretation of
FDG-PET/CT studies in the head and neck may be quite
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challenging due to the inherently complex anatomy, physiolog-
ical variants and unusual patterns of FDG uptake after radiation
therapy and surgery [1–4, 6–9]. Because FDG is not a tumour-
specific tracer, it can accumulate in a variety of benign processes
including benign tumours, inflammatory, post-traumatic and
iatrogenic conditions. Benign non-physiological FDG uptake
may be seen in up to 25%ofwhole-body PET/CTexaminations,
and FDG uptake may mimic malignant tumours in more than
half of these lesions [10]. Lesion characterisation on the CT
portion of the PET/CT study is therefore of utmost importance
as it increases the specificity of PET/CT reporting [10]. Although
FDG interpretation pitfalls are common in the head and neck,
they have received only very limited attention in the literature.
The purpose of this review is to discuss the most common
interpretation pitfalls in the purview of head and neck PET/CT
and how to avoid them. The added value of contrast-enhanced
CT (CECT) and/or magnetic resonance imaging (MRI) with
diffusion-weighted imaging (DWI) sequences or ultrasound
(US) to solve diagnostic dilemmas is equally discussed.
PET/CT imaging protocols
A detailed discussion of institutional PET/CT protocols used
in head and neck cancer patients is beyond the scope of this
article. Nevertheless, familiarity with the basic principles of
PET/CT imaging in head and neck oncology is important as
biological factors and the choice of imaging parameters, such
as field of view (FOV), slice thickness or use of iodinated
contrast material may influence the interpretation of PET/CT
findings. In most institutions, head and neck tumour patients
will often undergo a standard PET/CT examination without
intravenous contrast material; the area investigated typically
extends from the mid-forehead to the mid-thigh. Nevertheless,
an increasing number of authors advocate the additional use of
a dedicated high-resolution head and neck PET/CT (HR HN
PET/CT) with small FOV, longer acquisition time per bed
position and thinner slice thickness [11–13]. The additional
use of intravenous contrast allows full diagnostic CT capabil-
ity [11, 12] and improves diagnostic performance in the head
and neck area [14]. HRHN PET/CT is of particular help in the
identification of subtle morphological findings essential for
the diagnosis of local tumour spread and for the detection of
small lymph node metastases and recurrent disease, thus re-
ducing false-negative PET/CT readings (see below). Routine-
ly, PET/CT examinations are performed after a 6-h fasting
period and when the measured intravenous serum glucose
concentration prior to study begin is within normal limits
(<200 mg/dl). In general, 150–555 MBq (about 5–6 MBq of
F18-FDG per kilogram of body weight) [15] are administered
intravenously and during the following 60-min uptake period
patients are encouraged to rest and to refrain from talking or
chewing PET/CT imaging of diabetic patients may be
problematic because elevated glucose levels can cause com-
petitive inhibition of FDG uptake in different tissues. Al-
though intravenous insulin before FDG injection is effective
in reducing glycaemia, it can cause increased FDG uptake in
muscle and fat. Therefore, in patients with very high glucose
levels (>200–250 mg/dl), scanning should be rescheduled if
reasonably convenient [2]. A spiral CT scan for attenuation
correction is obtained first, after which PET data are acquired.
This unenhanced CT scan can be used not only for the atten-
uation correction of PET data but also for PET/CT image
fusion thereby allowing precise lesion localisation. Typical
whole-body CT parameters include: 120 kV, 240 mAs,
1.5 mm collimation, 40 cm FOV, soft tissue and bone window
settings. PET data acquisition is usually started after CT with
3–6 min per bed position for a total of seven to nine beds
covering the area from the mid-forehead to the proximal thigh.
Typical whole-body PET parameters include: 168 PET ma-
trix, 4 iterations, 8 subsets, 4-mm pixel size. After the total
body PET acquisition, an HR CECT can be obtained for the
head and neck with the following parameters: 120 kV, 210
mAs, 0.64–0.75 mm collimation, 20–25 cm FOV (small FOV
compared with whole-body PET/CT) soft tissue and bone
window settings, intravenous bolus of 100 ml iohexol (CT
acquisition started 1 min after intravenous bolus). For the head
and neck area, PET acquisition parameters can be changed as
follows: 6–12 min bed time, 256 PET matrix, 6 iterations, 4
subsets, 1.82-mm pixel size [11]. As suggested by several
authors [11–13] and based on the experience in our institution,
it is of utmost importance to obtain HR PET/CT images
through the head and neck region with a separate acquisition
from the body part to allow for detection of small lesions.
Interpretation pitfalls
Avariety of potential FDG-PET/CT interpretation pitfalls and
artefacts can be observed on routine head and neck studies.
The most common interpretation pitfalls are caused by vari-
able physiological FDG uptake within Waldeyer’s ring, sali-
vary glands, muscles or brown adipose fat (BAT) and by
increased FDG uptake due to inflammatory and infectious
conditions, recent surgery, previous chemoradiation, contra-
lateral cranial nerve palsy and thyroid nodules with high
glucose metabolism. Less often, lesions may be missed on
PET/CT due to low FDG avidity, small lesion size or due to
low scanner resolution. Common artefacts seen in the head
and neck area are related to metallic implants and dental
hardware or may occur due to patient motion between the
CT and the PET acquisition. These interpretation pitfalls and
artefacts, their pathophysiological mechanisms and key imag-
ing features are discussed below. Special emphasis is put on
how to avoid misinterpretation of findings and when addition-
al imaging methods are of complementary value.
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Physiological FDG uptake in the head and neck
Within the head and neck region, physiological FDG uptake
(Fig. 1) is commonly seen in the mucosa of the soft and hard
palate, Waldeyer’s ring, major salivary glands, minor salivary
glands beneath the mucosa, extraocular muscles, neck, pha-
ryngeal and laryngeal muscles, brown adipose tissue, thyroid
gland and cerebral cortex [6–11, 15, 16].
Waldeyer’s ring
Low to moderate FDG uptake is normally seen in the lym-
phatic tissues of theWaldeyer’s ring (nasopharyngeal, palatine
and lingual tonsils) due to FDG accumulation in macrophages
and lymphocytes (Fig. 1). Physiological FDG uptake in lym-
phoid tissue can be symmetrical or asymmetrical. In patients
with moderate and symmetrical FDG uptake, image interpre-
tation is straightforward. Nevertheless, head and neck
extranodal non-Hodgkin’s lymphoma (NHL) and squamous
cell carcinoma (SCC) of the nasopharynx or base of the
tongue may be occasionally bilateral making interpretation
of images more difficult. In such cases it is imperative to look
for associated anatomical abnormality on CT, such as pres-
ence of asymmetry, mass lesion, loss of fat planes and infil-
tration of surrounding facial deep spaces; all of which could be
suspicious for tumour. Sometimes, asymmetrical focal uptake,
which may occur as a physiological variant, can make inter-
pretation of PET/CT images challenging (Fig. 2a). Since the
Waldeyer’s ring is a common site for the origin of NHL and
primary SCC of the head and neck, asymmetrical FDG uptake
by normal lymphoid tissue may act as a confounding factor in
the identification of these tumours. Detailed anatomical eval-
uation by CECT or MRI (Fig. 2b) and clinical evaluation
including endoscopy with biopsy may be necessary to reach
the correct diagnosis [1–4, 6–9]. In the absence of anatomic
abnormality, some authors have suggested that ratios of
standardised uptake values (SUVs) of the normal to abnormal
side may help in reaching the diagnosis. For example, some
authors describe a statistically significant (P<0.001) SUV
difference between benign uptake (3.0 ± 1.16) and malignant
uptake (7.03 ± 3.83) in the nasopharynx [16]. Also, SUV
ratios of lateral nasopharyngeal recess uptake to the palatine
tonsil are significantly lower in benign compared with malig-
nant lesions and may be used to differentiate nasopharyngeal
cancer from physiological FDG uptake [16]. Similarly, the
mean SUVmax ratio of the two tonsils may be used as an
accurate biomarker to differentiate between tonsillar SCC and
physiological FDG uptake [17]. Davidson et al. [17] found
that in patients with tonsillar cancer, the mean difference in
SUVmax between tonsils was 10.43±7.07, which was signif-
icantly greater than that in control subjects (0.62±0.54;
P<0.0001 and the mean SUVmax ratio between tonsils in
patients with carcinoma was threefold higher than in control
subjects (3.79±1.69 vs 1.18±0.13; P<0.0001).
Salivary glands
FDG is physiologically taken up by the salivary glands and
excreted into saliva. Low to high FDG symmetrical uptake is
noted in the parotid and submandibular glands (Fig. 3). Be-
nign conditions like sarcoidosis, tuberculosis, viral infections,
bacterial infections, obstructive lithiasis and radiation-induced
sialadenitis can also cause increased FDG uptake in the sali-
vary glands. Asymmetrical salivary gland uptake in the floor
of the mouth can mimic focal areas of oral cavity malignancy.
Asymmetrical submandibular gland uptake can be seen in
patients who have undergone surgical removal of a gland with
contralateral hypertrophy and in patients who have undergone
unilateral radiation therapy [2–4, 6–9] (Fig. 4). This focal
asymmetrical uptake may occasionally mimic metastatic
Fig. 1 Axial PET CT images
showing physiological
symmetrical uptake in the
nasopharyngeal tonsils (arrows in
a) and in the mucosa of the hard
palate and minor salivary glands
beneath it (arrow in b)
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adenopathy at level IB or II [4]. While symmetrical diffuse
uptake in the salivary glands may be physiological (Fig. 3),
focal, asymmetrical uptake may also be suggestive of FDG-
avid benign or malignant salivary gland tumours like Warthin
tumour, pleomorphic adenoma, primary parotid lymphoma or
intraparotid lymph node metastasis from skin cancer. The
SUVs of most malignant parotid tumours are significantly
higher than those of benign lesions. However, some benign
tumours may show very high FDG uptake (typically Warthin
tumours), thereby mimicking malignant disease, while a few
malignant parotid gland neoplasms (typically adenoid cystic
carcinomas, low grade mucoepidermoid carcinoma or necrot-
ic SCC) may have no significant FDG avidity [2, 4, 9, 18–20].
Also, some studies show that high-grade salivary gland ma-
lignancies are associated with higher SUVs compared with
low grade malignancies [20]. Smaller salivary gland tumours
may be missed on CECT. Hence, in the presence of a focal
asymmetrical FDG uptake, further evaluation with ultrasound
(US)/US-guided fine needle aspiration cytology (US FNAC)
and/or MRI is often mandatory to reach the definitive
diagnosis [7, 18–20]. Due to wide availability, low cost and
high diagnostic accuracy, US is commonly used as a problem-
solving modality for the evaluation of salivary gland condi-
tions [21–23]. Many authors advocate the use of US FNAC
for the pre-operative evaluation of parotid masses due to its
good diagnostic accuracy. One study [24] shows that the
positive predictive value of US FNAC for diagnosing parotid
malignancy was 84.6 % and the negative predictive value was
96.4 %. Although MRI is mostly used for the precise assess-
ment of tumour spread, it can also be used as an adjunct to
differentiate between benign and malignant salivary gland
tumours. Malignant salivary gland tumours are often associ-
ated with ill-defined margins, low T2 signal due to high
cellularity, perineural spread most often along the facial nerve
(when originating in the parotid gland), invasion of the man-
dible, skull base, subcutaneous fat or skin and lymph node
metastases [25]. Nevertheless, these signs may be absent in
small-sized or well-differentiated malignant tumours, making
differentiation from benign lesions difficult. Quantitative anal-
ysis with DWI may be of help as the mean apparent diffusion
Fig. 2 a Axial PET/CT image
reveals asymmetrical FDG uptake
in the nasopharynx (arrow) in a
patient with SCC of the floor of
the mouth. Opacification of the
right maxillary sinus due to
mucous retention (asterisk). b
Axial T2-weighted MR image at
the same level depicts
symmetrical lymphoid tissue
within the nasopharynx without
underlying pathology. Endoscopy
confirmed absence of tumour.
Mucous retention in the right
maxillary sinus (asterisk)
Fig. 3 Axial PET/CT images
obtained at the level of the parotid
glands (a) and submandibular
glands (b). Physiological
symmetrical and high FDG
uptake in both parotid glands
(arrows) without underlying
pathology. Physiological slightly
asymmetrical and moderate FDG
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coefficient (ADC) of benign tumours (1.72×10−3 mm2/s is
often higher than that of malignant tumours (1.05×10−3 mm2/
s (P<0.001) [26], with the exception of Whartin tumours,
which typically show very low ADC values.
Muscles
Physiological FDG uptake is often seen in the muscles of the
head and neck, which can constitute a diagnostic dilemma in
the interpretation of PET scans [2–4, 6–9]. Prominent physi-
ological uptake can be seen in the tongue and in the pterygoid
muscles on vocalisation and chewing after FDG injection.
Prominent FDG uptake is also often seen in the extraocular
muscles due to eye motion. In the neck, physiological FDG
uptake can be seen both in the visceral and non-visceral
compartment musculature. In the visceral compartment, pro-
nounced uptake in the cricopharyngeus and posterior
cricoarytenoid muscles on phonation can interfere with the
interpretation of PET scans in patients with hypopharyngeal,
oesophageal and thyroid cancers, in whom this physiological
uptake may mimic pathology [2, 4, 6, 27]. Uptake in the
anterior portion of the genioglossus muscles can mimic or
obscure small floor of the mouth cancers. Contraction-
induced increased FDG uptake in the cervical muscles, strap
muscles and paraspinal muscles in anxious patients (in partic-
ular sternocleidomastoid, scalenus anterior, longus colli,
longus capitis and inferior obliquus capiti muscles) can mimic
lymph node metastasis or, alternatively, may lead to false-
negative findings obscuring disease truly present in underly-
ing lymph nodes [2–4, 6–9, 28, 29]. Uptake in the anterior
scalenus muscle mimicking supraclavicular lymph node me-
tastasis in a case of lung cancer has been described [29].
Muscle uptake is generally linear and can be traced from the
origin to insertion on fused PET/CT images (Fig. 5) Therefore,
careful analysis of two-dimensional (2D) multiplanar recon-
structions in the coronal and sagittal planes is mandatory
whenever findings are unclear on axial PET/CT images [2,
4, 7–9, 28]. The administration of benzodiazepines before
FDG injection helps to decrease muscle uptake; however, it
is rarely done in clinical routine. Also, patientsmay be advised
Fig. 4 a Axial PET/CT image demonstrates asymmetrical FDG uptake
of the tonsillar fossae (arrowhead) and parotid glands (increased uptake
on the left, arrow) in a patient previously irradiated for SCC of the right
base of the tongue with sparing of the left side. Note increased FDG
uptake of the non-irradiated left parotid gland (arrow) and fatty infiltra-
tion of the irradiated right parotid gland (asterisk). b Corresponding axial
contrast-enhanced T1-weighted image shows no pathological findings in
the left tonsillar fossa (arrowhead) and left parotid gland (arrow). Note
atrophy and fatty infiltration of the right parotid gland (asterisk). c
Corresponding b1,000 DW MR image reveals physiological
hyperintensity in the tonsillar fossae more pronounced on left
(arrowhead) compared with the right (arrow) due to normal lymphoid
tissue on the left and atrophy of lymphoid tissue on the right. d Corre-
sponding ADCmap showing physiologically low ADC values on the left
(arrowhead) due to normal lymphoid tissue. Dashed arrows point at
radiation port on the right
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to stay relaxed and avoid talking, eating and chewing after the
injection of FDG [7–9, 28]. A further factor influencing FDG
uptake in muscle is insulin. Insulin administration prior to
FDG PET/CT leads to increased accumulation of FDG in
muscle, degrading image quality and hampering correct image
interpretation [2].
Brown adipose tissue (BAT)
BAT can occur anywhere in the neck. It is, however, most
often encountered in the lower neck and upper mediastinum.
High physiological FDG uptake in BAT may sometimes
mimic metastases (Fig. 6). Sympathetic stimulation stimulates
brown adipocytes and increases their metabolic activity, lead-
ing to increased FDG uptake. A typical finding of BAT-related
FDG uptake is symmetr ical FDG uptake in the
supraclavicular, mid-axillary, paraspinal and posterior medi-
astinal regions. These areas show fat attenuation (−50 to −150
Hounsfield units [HU]) on the corresponding CT images.
Precise PET/CT image fusion, careful analysis of CT images
and knowledge of human BAT distribution help to avoid
misdiagnosis of brown fat deposits for pathology [2, 4, 6–9,
30]. Hypermetabolic BAT is more commonly seen in children
than in adults and is more prevalent in females than in males.
It occurs more frequently in patients with low body mass
index and in cold weather [30]. Some authors describe varia-
tions in supraclavicular BAT FDG uptake in breast cancer
patients after chemotherapy with drugs like docetaxel [31].
Hibernomas are benign fatty tumours arising from vestigeal
fetal brown fat and are usually seen in the neck, back and
mediastinum. These benign lesions often show intense FDG
uptake, thereby mimicking soft tissue sarcomas [32]. FDG
uptake in brown fat can be reduced pharmacologically with
beta-blockers and benzodiazepines, if necessary [6–8].
Increased FDG uptake potentially causing false-positive
findings
Inflammation and infection
As mentioned above, benign conditions like inflammation,
infection and granulomatous diseases may show increased
FDG uptake in head and neck cancer patients, thereby mim-
icking malignancy. The uptake in these cases is attributed to
increased glycolysis in activated inflammatory cells (mainly
macrophages). Increased FDG uptake is typically seen at sites
of infection, indwelling ports and catheters, foreign body
granulomas, reactive nodes, vasculitis and in active athero-
sclerotic plaques (Fig. 7), [1, 3, 4, 7–10, 33–37]. Recent
studies have shown that FDG uptake not only allows reliable
identification of vulnerable plaques in the carotid arteries but
also reflects the severity of atherosclerotic vessel wall inflam-
mation [36]. Therefore, precise image fusion between PET
and CT data sets, as well as correlation with CECT, is neces-
sary to avoid misdiagnosis of carotid plaque uptake as meta-
static lymph nodes (Fig. 7). This pitfall is typically encoun-
tered when only unenhanced CT scans are available for image
interpretation and whenever patient motion between the CT
and the PET acquisition leads to mis-coregistration of images
(see below).
Often the clinical history points to the cause of FDG
uptake; however, inflammatory conditions (such as periodon-
tal disease, dental infection, active atherosclerotic plaques or
tuberculosis) and neoplastic disease can coexist. Reactive
nodes are commonly encountered in the head and neck, and
may result in a decreased specificity of FDG-PET/CT for the
nodal staging of head and neck cancers. Precise image fusion,
correlation of PET with morphological CT findings and 2D
multiplanar reconstructions are essential in order to avoid
overdiagnosis of benign conditions as malignancy, as well as
missing out on actual pathology. Evaluation of SUVs may
help to differentiate between benign and malignant disease,
whereby SUVs greater than 3 are considered as a general
guide to indicate neoplasm. Nevertheless, SUVs greater than
3 can also occur in acute infection, such as sinusitis, osteo-
myelitis, suppurative lymphadenopathy and abscess. If diag-
nostic dilemma still exists, sequential follow-up imaging, US
examination of the neck and, at times, US FNAC may be
needed [1, 3, 4, 7–9, 33, 34, 38, 39].
Other than osteomyelitis and reactive nodes, inflammation
of salivary gland parenchyma and of salivary ducts can con-
stitute a diagnostic pitfall (Fig. 8). Increased salivary gland
uptake can be seen in obstructive as well as non-obstructive
sialadenitis. In obstructive sialadenitis, the increased FDG
uptake can be explained by the accumulation of excreted
FDG in the dilated ductal system. The FDG uptake seen in
non-obstructive sialadenitis is caused by activated white blood
cells, increased levels of glucose transporters (mainly GLUT 1
and GLUT 3), cytokines and growth factors [10]. Careful
correlation of FDG uptake with morphology, as depicted on
the CT or CECT part of the PET CT is essential for diagnosis
(Fig. 8). CECT findings in sialadenitis include major enhance-
ment of gland parenchyma, reticulated aspect of peri-glandular
fatty tissue due to phlegmon and, occasionally, the presence of a
small abscess. CECT is less sensitive than US for the detection
of early sialadenitis and sialolithiasis. Hypoechoic gland paren-
chyma, increased vascularisation on Doppler images and
blurred gland margins are characteristic findings on US.
Inflammation caused by radiotherapy and chemotherapy
Chemoradiation is one of the mainstays in the treatment of
head and neck cancers. FDG-PET is now routinely used for
the differentiation of residual and recurrent tumours from
post-radiotherapy changes, where anatomic imaging like CT
or MRI can be difficult. FDG-PET/CT has a very high
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sensitivity (between 90 and 100 %) and very high negative
predictive value (about 97 %) for the detection of tumour
recurrence [1, 40–42]. However chemoradiation causes in-
flammation, oedema, hyperaemia, fibrosis and loss of tissue
planes. The presence of post-treatment inflammatory tissue
can cause increased FDG uptake, which may be confused for
residual tumour (Fig. 9). There may also be considerable
overlap in the SUVs of post-radiotherapy inflammatory tissue
and tumour recurrence; in particular, regarding lymph node
imaging. It is, therefore, recommended that follow-up PET/
CT should be deferred for at least 2–3 months after chemo-
radiotherapy to avoid false-positive results, with many authors
advocating 12 weeks after treatment as the optimal timing [1,
3, 4, 9, 33, 34, 40–42].
Even if PET/CT is obtained after 12 weeks following
completion of chemoradiation, false-positive findings may
Fig. 5 HIV positive patient with
SCC of the left piriform sinus. a
Axial PETCT illustrates a nodular
area of high FDG uptake at left
level II (asterisk) and bilateral
nodular areas of symmetrical high
FDG uptake laterally in the neck
(arrows). There is an additional
nodular area of high FDG uptake
in the right retropharyngeal region
(arrowhead). All nodular areas of
high FDG uptake appear to
represent metastatic adenopathy.
b Corresponding axial CECT
image shows an enlarged
enhancing left level II node
(asterisk). No suspicious
adenopathy is seen at the other
sites of increased FDG uptake
including the lateral sides of the
neck as well as the right
retropharyngeal region. c
Corresponding coronal PET/CT
image confirms the linear nature
of the foci of high FDG uptake in
both sternocleidomastoid muscles
(arrow) and in the right longus
colli muscle (arrowheads). Areas
of avid nodular FDG uptake are
seen at left level II and III
(asterisks). d Corresponding
coronal CECT image confirms
that the linear areas of FDG
uptake correspond to neck
muscles. Metastatic cervical
adenopathy is confirmed at left
level II and III (asterisks). The
high uptake in the right longus
colli and bilateral
sternocleidomastoid muscles was
related to involuntary contraction
in this very anxious patient
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still occur. Post chemo-radiotherapy false-positive findings on
PET/CT are caused by radiation-induced mucositis, reactive
nodes, soft tissue necrosis and radionecrosis of bone [4, 8, 9,
33, 41]. CECT and MRI may also be equivocal in these
situations. Radiation-induced mucositis is a common sequel
of chemo-radiotherapy for oropharyngeal and laryngeal SCC
and can persist for prolonged periods after treatment. Diffuse
mild FDG uptake along the oropharyngeal and laryngeal walls
are in keeping with inflammation; however, a more focal
uptake should raise suspicion for ulceration or persistent dis-
ease. Osteoradionecrosis is a late complication of high-dose
irradiation for squamous cell carcinoma of the oral cavity,
pharynx and larynx, and constitutes a lifelong problem for
cancer survivors. It can affect the jaws, larynx and hyoid bone,
Fig. 6 a Axial PET/CT image
depicts bilateral symmetrical
areas of avid FDG uptake in the
supraclavicular regions (arrows).
These may be confused for
metastatic supraclavicular
adenopathy. b Corresponding
axial CECT image detects no
focal abnormality in the
supraclavicular regions (arrows).
Note that the areas of high uptake
seen in a correspond to low
attenuation fatty tissue (arrows) in
b
Fig. 7 a Axial PET/CT image depicts a focal nodular area of high FDG
uptake at right level II (arrow) and at the left base of tongue (arrowhead).
This patient was a follow-up case of SCCof the right floor of mouth. The
nodular FDG uptake at right level II was considered suspicious for nodal
recurrence whilst the focal FDG uptake at the left base of tongue was
ascribed to probable lymphoid tissue uptake. b Corresponding axial
CECT image detects no evidence of metastatic cervical adenopathy at
right level II. The focal FDG uptake at right level II corresponds to partly
calcified plaques in the right internal and external carotid arteries (arrow).
Follow-up confirmed no lesion in the left base of the tongue
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cervical spine, central skull base or temporal bone [43–45].
Although the risk of developing osteoradionecrosis has sig-
nificantly diminished in recent years [44], osteoradionecrosis
of the jaws and of the skull base still constitutes a common
pitfall of FDG-PET/CT imaging [45, 46]. Often,
osteoradionecrosis lesions show very high SUVs, equalling
that of residual/recurrent tumour, and there is a significant
overlap of SUVs in patients with osteoradionecrosis and tu-
mour recurrence [46]. Correlation with CT images may help in
some instances, as the prevalence of bony sclerosis is signifi-
cantly more common in osteoradionecrosis, whereas recurrent
tumours rather display solid or cystic soft tissue masses [46].
Nevertheless, in equivocal cases, a short-term follow-up PET/
CT or MRI with diffusion-weighted sequences (DWI) may be
additionally used for the differentiation between radiation-
induced changes and residual/recurrent disease [4, 9, 33, 47].
Analysis of ADC values may help distinguish between residual
cancer and benign post-treatment changes. Residual or recur-
rent SCCs show significantly lower ADC values than that of a
benign post-treatment mass, with an ADC threshold value of
around 1.3×10−3 mm2/s [47]. Due to their capability to obtain
anatomical, functional and metabolic information in a single
examination, hybrid PET/MRI systems hold promise to facili-
tate differentiation between radiation-induced changes and
recurrent disease [5, 48–51]. Nevertheless, very little data are
currently available regarding the clinical implementation of
hybrid PET/MRI scanners in the head and neck [5, 48–51],
and future studies will show whether PET/MRI outperforms
PET/CT, DWI MRI or the combination of these techniques.
Inflammation caused by recent surgery
Depending on institutional choices, surgery may be preferen-
tially performed in patients with advanced nodal disease, in
patients with oral cavity cancers or in patients with recurrent
disease after chemoradiation. Although the morphological
changes are straightforward after radical or functional neck
dissection, partial glossectomy and total or partial laryngecto-
my, interpretation of the post-surgical neck may be more
complicated in cases with reconstructive procedures using
grafts or flaps (free or pedicle) and in cases with combined
surgery and chemoradiation. Due to the confusing surgical
anatomy, recurrent tumours are more easily identified with
PET/CT than with CT alone due to the increased focal uptake
of recurrent disease. Nevertheless, after surgical removal of a
gland or muscle the contralateral gland or muscle may show
increased FDG uptake (Fig. 10) mimicking tumour recurrence
and careful analysis of postoperative neck changes can help to
Fig. 8 Axial (a) and coronal (b)
PET/CT images illustrate high
FDG uptake of the right
submandibular gland (arrows)
and soft tissues of the neck
(asterisk) in a patient investigated
for histiocytosis. The left
submandibular gland
(arrowhead) shows moderate
FDG uptake. Note that the
hypermetabolic submandibular
gland can be easily mistaken for
lymphadenopathy unless coronal
images are carefully analysed.
Corresponding axial (c) and
coronal (d) CECT images reveal
slightly increased enhancement of
the right submandibular gland
(arrows), reticulated aspect of
subcutaneous fatty tissue
(asterisk) and thickening of the
right platysma muscle due to
sialadenitis with phlegmon.
Dashed arrows in d point at the
phlegmon extending cranially in
the masticator space. US revealed
lithiasis as the cause of
sialadenitis
Insights Imaging (2014) 5:585–602 593
solve this diagnostic dilemma. Post-surgical inflammatory
oedema, scarring and granulation tissue can also cause in-
creased FDG uptake making the interpretation of PET/CT
studies very difficult in particular if the CT part of the PET/
CT study comprises only a low dose CT for attenuation
correction or if no CECT images are available (Fig. 10).
Granulation tissue is the first step in wound healing and
develops from connective tissue around the damaged area
[52, 53]. It mainly contains inflammatory cells, fibroblasts,
myofibroblasts and small vessels [52]. Over time,
myofibroblasts and small vessels gradually disappear and
granulation tissue evolves into immature and thenmature scar.
The mechanism responsible for this process is granulation
tissue apoptosis, which mainly occurs between 20 and 25 days
after injury, the fibroblastic apoptotic cells being continuously
removed by macrophages [52]. Histological and morphomet-
ric studies have shown that the transformation of granulation
tissue into scar tissue usually takes place within the first
2 months of injury [52], However, the duration of this process
may vary depending on the amount of damaged tissue. As this
transformation is a continuous process, there is a smooth
transition between granulation tissue, early (immature) scar
with limited amount of collagen and late (mature) scar with
significant collagen deposition. Major FDG uptake, as seen on
PET/CT images, is typically seen during the first weeks to
months after surgery; it tends to decrease gradually over time.
Post-surgical anatomical distortion can further increase the
diagnostic dilemma in such cases. Therefore, it is generally
recommended that the follow up PET/CT be performed at
least 4–6 weeks after surgery after acute inflammation has
subsided. Detailed knowledge of the previous surgical proce-
dure and surgical complications (abscess, phlegmon, flap
necrosis) helps to avoid diagnostic errors. Occasionally, to
make the PET/CT image fusion precise, an additional MRI
may be necessary to avoid misdiagnosis [1–4, 8, 42] (Fig. 10).
Contralateral cranial nerve palsy
Asymmetrical FDG uptake in the vocal cords can be seen in
patients with recurrent laryngeal nerve palsy from prior surgical
intervention or tumour involvement or due to trauma. The
compensatory activation of the non-paralysed vocal cord leads
to increased metabolism and increased glucose consumption,
especially in the thyroarytenoid muscle and in the posterior
cricoarytenoid muscle; this increased metabolism is seen as a
focal hypermetabolic spot on FDG PET images (Fig. 11). This
imaging mimic may be confused with a tumour in the non-
paralysed vocal cord unless CT images are carefully analysed
[2, 4, 7, 8, 54–57]. On the contrary, if no FDG uptake is seen in
both vocal cords and only in the posterior cricoarytenoid mus-
cle, the interpreter may overlook vocal cord paralysis on FDG-
PET/CT. Characteristic CT imaging findings of recurrent laryn-
geal nerve paralysis include paramedian position of the
paralysed vocal cord, displacement of the ipsilateral arytenoid
cartilage, compensatory medial rotation of ipsilateral
aryepiglottic fold, dilated ipsilateral pyriform sinus and atrophy
of posterior cricoarytenoid and thyroarytenoid muscles [4, 55,
57, 58]. PET/CT image fusion and clinical correlation can help
to overcome this potential pitfall. History of hoarseness, prior
surgery or radiation in the neck, larynx, thyroid or mediastinum
Fig. 9 a Axial PET/CT image shows a hypermetabolic focus in the left
infratemporal fossa (white arrow). This patient was a follow-up case of
SCC of the left retromolar trigone, 6 months post radiotherapy, presenting
with left V3 distribution pain and dysesthesia. b Corresponding axial
contrast-enhanced T1W MR image demonstrates nodular architectural
distortion with some enhancement (white arrow) in the left infratemporal
fossa. c Corresponding axial CECT image reveals similar morphologic
findings as the MR image: an ill-defined area of nodular enhancement
(white arrow) in the left infratemporal fossa. The imaging differentials
were tumour recurrence along left V3 nerve or post-radiotherapy imma-
ture (early) scarring. Surgery was negative for tumour recurrence and
careful histologic analysis of the resected specimen yielded fibrotic scar
tissue. Follow-up over a period of three years confirmed absence of
recurrent disease
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may indicate injury to one of the recurrent laryngeal nerves [4,
55–57]. Laryngoscopic examination will help to confirm im-
paired movement of the contralateral vocal cord and also will
rule out a primary pathology in the ipsilateral cord. However, any
nodularity or apparent lesion in the vocal cord with focal FDG
uptake is suspicious and warrants further evaluation [55–58].
Palsy of the hypoglossal nerve (XII), spinal accessory
nerve (XI) or the mandibular division of the trigeminal nerve
Fig. 10 a Axial PET/CT image
shows intense FDG uptake in the
right root of the tongue and floor
of the mouth (asterisk) in a patient
with recent surgical resection of
recurrent SCC of the left
hemitongue. b Corresponding
axial non-contrast CT image
confirms post-surgical
architectural distortion without an
obvious underlying mass lesion
(asterisk) on the right.
Corresponding axial T2W (c) and
contrast-enhanced T1W (d)
images reveal a linear band of low
signal intensity scar tissue on the
left (arrows). No tumour is seen
on the right (asterisks). Muscle
architecture in the right floor of
the mouth appears normal on T2





findings due to contralateral
scarring were considered as the
cause of this unusually high FDG
uptake. Follow-up of 2 years
confirmed absence of recurrence
Fig. 11 a Axial PET/CT image demonstrates a focal area of avid FDG
uptake in the right true vocal cord (arrow) suspicious for a tumour lesion.
b Corresponding non-contrast axial CT image shows no definite focal
lesion in the right vocal cord. CT images at other levels of the larynx were
normal. Clinical history mentioned recently diagnosed left vocal cord
paralysis confirmed by fibre optic endoscopy. This compensatory in-
creased uptake in the right vocal cord was due to recent left vocal cord
paralysis. This case illustrates the need for rigorous correlation with
clinical findings whenever the only abnormality observed is unilateral
vocal cord FDG uptake
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(V3) may also result in contralateral intense FDG muscle
uptake. CT findings in long standing V3, XI and XII palsy
are pathognomonic and usually do not require further imaging
as long as the cause of nerve injury is known [59, 60]. In long
standing XII palsy, CT reveals atrophy of the affected
hemitongue with fatty infiltration, a clear-cut linear demarca-
tion between the affected and non-affected muscles as well as
tongue deviation. Prolapse of the paralysed hemitongue into
the oropharynx when the patient is in the supine position is a
further characteristic finding.
In long-standing XI palsy, CT shows atrophy of the ipsi-
lateral sternocleidomastoid and trapezius muscles (Fig. 12)
and compensatory hypertrophy with focal or diffuse hyper-
metabolic FDG activity. In V3 palsy, fatty infiltration of the
muscles of mastication (medial and lateral pterygoid, masseter
and temporalis muscles), as well as of the tensor tympani, the
anterior belly of the digastric and mylohyoid muscles are seen;
contralateral muscle hypertrophy and increased FDG uptake
are less often present at imaging.
In early muscle denervation due to recent palsy, muscle
atrophy is not obvious on CT and contralateral compensatory
FDG uptake may be mistaken for non-specific tracer accumu-
lation or contralateral tumour in particular in the tongue [61].
Partial glossectomy can cause tongue fasciculations, which
Fig. 12 aAxial PET/CT image reveals compensatory FDG uptake of the
left sternocleidomastoid muscle (white asterisk) and of the ipsilateral
trapezius muscle (black asterisk) due to right spinal accessory nerve
(XI) paralysis caused by a base skull adenocarcinoma. Also note atrophy
of the right sternocleidomastoid muscle (dotted arrow) and of the right
trapezius muscle (arrow). b Corresponding coronal PET/CT image de-
picts atrophy of the right trapezius muscle (arrow) and compensatory
increased uptake of the left trapezius muscle (black asterisk)
Fig. 13 a Coronal PET/CT image
illustrates a focal nodular area of
high FDG uptake within the left
thyroid lobe (white arrow), which
can reveal an underlying
malignancy in 25–50 % of cases.
Therefore, US FNAC is
recommended. b Corresponding
coronal CECT image shows a
small hypodense nodule within
the left thyroid lobe (white
arrow), corresponding to the
focus of high FDG uptake on
PET/CT. Subsequent US FNAC
of the left thyroid nodule and
follow-up over a period of 2 years
yielded benign thyroid nodule,
thereby indicating that the PET/
CT result was false-positive for
malignancy
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can lead to false-positive FDG uptake, thereby mimicking
recurrent tumour [4, 33]. As MRI is more sensitive than
CT for the detection of early signs of muscle denervation,
correlation with MRI findings and with clinical data in-
cluding electromyography helps to overcome this pitfall
[4, 33].
Increased FDG thyroid gland uptake
The thyroid gland may show various appearances on PET
studies with diffuse symmetrical FDG uptake, focal asymmet-
rical uptake or at times, no uptake [2, 6–8, 62, 63]. Various
physiological, benign and pathological processes may be
causative for these different patterns of FDG uptake. Mild
diffuse symmetrical uptake may be seen in normal thyroid
glands, in diffuse goitres or in autoimmune thyroiditis, where-
as focal uptake may be seen in adenomatous nodules and
thyroid malignancy [2, 6–8, 62, 63]. Although some authors
state that the maximum SUV of malignant thyroid lesions is
significantly higher than that of benign lesions (6.7±5.5 vs
10.7±7.8; P<0.05) [63], the reported risk of malignancy in an
area of focal FDG uptake in the thyroid ranges from 36–63 %
[62, 63]. Therefore, all focal areas of moderate to intense FDG
uptake in the thyroid gland should be further assessed with an
US examination and US FNAC to exclude thyroid cancer
(Fig. 13). Another potential imaging pitfall is the likely mis-
diagnosis of focal thyroid uptake as metastatic disease in the
lower cervical nodal stations [64]. Precise image fusion helps
to resolve this diagnostic dilemma [64]. However, in patients
who have moved between the CT scan and the PET acquisi-
tion, it may be difficult to differentiate between metastatic
level IV lymph nodes and small thyroid nodules, in particular
in small-sized lesions. In our institution, we routinely perform
an US examination of the neck in these situations and, if
necessary, US FNAC.
Factors potentially causing false negative PET/CT readings
Low FDG uptake, low image resolution and small lesion size
Some salivary gland tumours—like adenoid cystic carcinoma,
spindle cell neoplasms, extranodal marginal zone lymphomas,
as well as necrotic tumours or necrotic lymph node metasta-
ses, well-differentiated sarcomas and some thyroid carcino-
mas—may not be FDG-avid, thereby yielding false-negative
results (Fig. 14). FDG-PET/CT is therefore not recommended
for evaluating these tumours. [1, 3, 4, 9, 19, 42, 65]. Low-
grade tumours may show lower FDG uptake than their high-
grade counterparts [20, 66]. Also, necrotic lymph nodes may
not contain sufficient metabolically active tissue to show FDG
uptake, even though the primary solid neoplasm may show
FDG uptake. This potential pitfall must be considered to avoid
false-negative results [1, 3, 4, 9, 19, 33, 42].
Small-sized malignant tumours (diameter below 6–8 mm)
and especially small-sized metastatic lymph nodes may not be
detected by PET/CT unless intense FDG uptake is present
because these lesions are below the resolution of current PET
scanners (Fig. 15). Partial volume effect may cause significant
decrease in perceived SUV in such small lesions and thereby
yield a false-negative result. This pitfall can be partly overcome
today by using dedicated HR PET/CT acquisitions (see above),
whereas future developments in PET detector technology hold
promise to further improve scanner resolution [1, 4, 9, 33, 42,
67].
Lesion proximity to areas with high metabolism
Proximity of a pathological lesion to another FDG-avid lesion
or normal structure with high FDG uptake may lead to a false-
negative diagnosis. This is most commonly seen in skull base
tumours in the vicinity of highly metabolic brain parenchyma
or in small oral cavity tumours close to the tonsils, which
Fig. 14 aAxial PET/CT image demonstrates slight asymmetrical uptake
in the anatomic location of the longus colli muscles (arrow) in a patient
previously treated by right partial parotidectomy and radiation therapy for
a lymphoepithelial SCC of the right parotid gland. Note hypometabolism
of the residual right parotid gland (arrowhead) and focal uptake in the left
parotid gland. Corresponding axial CECT (b) and contrast-enhanced fat
suppressed T1-weighted MR (c) images illustrate a necrotic metastatic
retropharyngeal lymph node on the right side (arrows),mistaken on PET/
CT for minor prevertebral muscle activity and therefore yielding a false
negative evaluation. Note the diffuse and heterogeneous enhancement of
the remaining right parotid gland following surgery and radiotherapy
(arrowheads) better depicted on MRI as on CECT. There is no morpho-
logical abnormality in the left parotid gland. Left parotid gland uptake
seen on PET/CTwas attributed to compensatory hyperactivity
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show high physiological FDG uptake (see above) [3, 4, 9,
33, 68]. In the orbit, the high metabolic activity of
extraocular muscles acts as a further confounding factor
[69]. In addition, abnormalities of the skull base and orbit
tend to be overlooked on head and neck PET/CT examina-
tions also because they are often subtle and they are typi-
cally at the edge of the field of view [69]. Detailed anatomic
evaluation of the CT part of PET/CT is essential for the
detection of subtle obscuration of fat planes beneath the
skull base or bony erosion of skull-base foramina. Never-
theless, an additional MRI examination (Fig. 16) is often
necessary for the precise evaluation of tumour spread in
these specific regions. A common example of this pitfall
occurs in the evaluation of primary nasopharyngeal carci-
noma with FDG-PET/CT. FDG PET/CT is known to under-
estimate perineural spread, tumour involvement of the skull
base and cavernous sinuses compared with MRI, due to the
surrounding ‘shine through effect of FDG’ around the tu-
mour and because of the inferior conspicuity of these con-
ditions on CECT compared with MRI [4, 33, 70]. However,
the higher FDG accumulation in the tumour as compared to
that in the adjacent grey matter and changing the window
Fig. 15 a Axial PET/CT image shows no evidence of abnormal FDG
uptake or metastatic cervical adenopathy in the neck. Physiological mild
FDG uptake is seen in the thyroid gland, oesophagus and in the scalenus
muscles (dashed arrows). This patient was a follow-up case of a SCC of
the base of the tongue. b Corresponding CECT image (1 mm slice)
detects a 5 x 7 mm sized enhancing node at left level IV (white arrow).
This node did not show an increased FDG uptake on the PET acquisition
of the PET/CT (slice thickness of PET acquisition was 5 mm). US FNAC
revealed metastatic lymphadenopathy. Neck dissection confirmed metas-
tasis from HNSCC. Dashed arrows in b point at normal anterior scalenus
muscles
Fig. 16 a Axial PET/CT image shows asymmetric uptake in the naso-
pharynx (arrowhead) and expected high uptake in the explored hindbrain.
A lytic lesion in the clivus with well-defined sclerotic borders andwithout
FDG uptake is also detected (arrow). The remaining of the total body
PET/CT was normal. b Corresponding axial contrast-enhanced
T1weighted MR image obtained in the same patient illustrates an infil-
trative, poorly delineated tumour invading the clivus, the right jugular
fossa, the right petrous apex and the brainstem (arrows), not revealed by
PET/CT. Subsequent biopsy of the clivus, intracranially and of the
nasopharynx showed a primary adenocarcinoma of the skull base. The
increased FDG uptake in the left nasopharynx corresponds to tumour
invasion of the longus colli muscle. Due to intratumoral areas with
variable FDG avidity and due to tumor vicinity to the highly metabolic
brain parenchyma, this lesion is less well depicted by PET/CT than MRI
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and level settings on PET/CT scans may help to pick up the
lesion in some cases [48, 49]. Due to the close vicinity of
retropharyngeal lymph nodes to the nasopharynx, detection
of retropharyngeal nodal metastases with PET/CT may be
impossible and correlation with MRI is necessary for cor-
rect tumour staging [4, 33, 70] (Fig. 17). The recent intro-
duction of hybrid PET/MRI systems is expected to facilitate
image interpretation in these particular situations [5,
48–51]. Boss et al. have shown promising results for the
evaluation of skull base and suprahyoid neck tumours using
PET/MRI hybrid systems [49], and Vargas et al. [50] and
Varoquaux et al. [51] reported excellent PET/MRI image
quality and lesion conspicuity in head and neck cancer
patients. Nevertheless, PET/MRI systems are still not wide-
ly available [5] and ongoing research will clarify potential
future applications in the head and neck.
Common FDG-PET/CT artefacts
Artefacts related to dental hardware and metallic implants
Unremovable dental hardware and metallic implants are a
major problem in cross-sectional imaging of the head and
neck. They can severely degrade the visual appearance of
CTand CECT images by causing streak artefacts and affecting
the true distribution of Hounsfield units. These artefacts may
propagate to the PET images through CT-based attenuation
correction factors [2, 71]. Attenuation-correction artefacts
may negate the utility of CT for the spatial localisation of
PET findings. Because artefacts related to metal implants are
in general less pronounced on MRI scans, a combined inter-
pretation of PET/CT and MRI helps to avoid false-negative
readings and/or inaccurate tumour assessment (Fig. 18).
Fig. 17 a Axial PET/CT image reveals a FDG-avid mass in the naso-
pharynx in keeping with a known nasopharyngeal carcinoma (asterisk).
No separate retropharyngeal adenopathy is seen on this image. b Corre-
sponding axial CECT image shows the infiltrative nasopharyngeal carci-
noma (asterisk). No definite retropharyngeal adenopathy is seen. c Cor-
responding axial T2W MR image demonstrates the infiltrative
nasopharyngeal carcinoma (asterisk) and an enlarged left retropharyngeal
node (white arrow) suspicious for nodal metastasis. This nodewasmissed
on PET/CT due to its close proximity to the FDG-avid primary tumour
and on CECT due to poor soft tissue contrast as compared to MRI.
Detection of retropharyngeal lymph nodes in nasopharyngeal cancer
affects TNM classification
Fig. 18 a Axial PET/CT image demonstrates extensive streak artefacts
from right-sided dental implants in a patient with clinically proven SCCof
the right retromolar trigone. The known lesion in the right retromolar
trigone is completely obscured by the streak artefacts. b Corresponding
axial FDG-PET image depicts no uptake in the region of the right
retromolar trigone thereby yielding a false-negative result. c Correspond-
ing axial contrast-enhanced T1WMR image detects the infiltrative mass
in the right retromolar trigone (white arrows). The extent of the lesion as
seen onMRI was afterwards confirmed surgically. MRI is less affected by
dental artefacts as compared to CT
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Artefacts related to dental hardware and metallic implants also
affect measurements of SUV values on PET/CT [72]: while
SUVs tend to decrease in the dark streak artefact regions, they
increase significantly in the bright streak artefact regions [73].
Appropriate algorithms for the correction of metallic artefacts
on CT help to overcome this pitfall [72]. These algorithms help
to suppress the bright and dark streak artefacts, thereby increas-
ing the HUs in areas where values have been underestimated
and decreasing the HUs in areas where values have been
overestimated. Inspection of the emission data (non-attenua-
tion-corrected PET scan) often helps to resolve any uncertainty
regarding the presence of a CT-based attenuation artefact [2, 6,
74]. Recently, it has been suggested that dental streak artefacts
can be corrected during CT-based attenuation correction using
complementary MRI data [75].
Patient motion
Involuntary patient motion between the CT and the PET data
acquisition of a PET/CT study can lead to poor data fusion,
making correct localisation of focal uptake impossible especial-
ly in smaller lesions and in the supraclavicular area (see “In-
creased FDG thyroid gland uptake”). In addition, respiratory
mismatch or vigorous swallowing can also influence the quality
of PET/CT images as head and neck cancer patients often
present with major dyspnoea, coughing or swallowing prob-
lems. In order to optimise PET/CT image fusion, the respiratory
levels during the PETandCT data acquisition should be similar.
Therefore, in most institutions, patients are asked to breathe in a
shallow fashion during the neck acquisition and refrain from
vigorous inspiratory or expiratory manoeuvres. In addition to
adequate patient instruction, immobilisation during scanning
often prevents motion artefacts. Nevertheless, it is important
to point out that mis-coregistration artefacts from patientmotion
are a lesser problem in head and neck PET/CT studies com-
pared with PET/CT scans of the chest or abdomen.
Conclusions
FDG-PET/CT imaging has dramatically changed head and
neck cancer imaging and management. FDG, however, is
not tumour-specific and various image interpretation pitfalls
may occur due to false-positive and false-negative causes of
FDG uptake. This article reviews the causes of physiological
FDG uptake in the head and neck, and of uncommon patterns
of uptake due to benign lesions, artefacts, recent surgery,
inflammation and scarring. Awareness of these tumour
mimics along with accurate clinical information, detailed an-
atomical evaluation and—if necessary—correlation with oth-
er imaging modalities, such as CECT, US or MRI help to
avoid misinterpretation of head and neck PET/CT studies.
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